pharma · COVID-19 · Hepatitis C · AVIR
Atea Pharmaceuticals
Atea Pharmaceuticals patent portfolio — 35 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US
- Founded
- 2014
- Employees
- 57
- Programs
- 37
- Drugs
- 29
- Patents
- 35
Atea Pharmaceuticals patents
35 pharmaceutical patents indexed for Atea Pharmaceuticals. 0 expire within 24 months.
Atea Pharmaceuticals has 35 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12226429
Highly active compounds against COVID-19
granted -
US 12084473
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 11975016
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 11964047
Ophthalmic formulations and related methods
granted -
US 11833160
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
granted -
US 11813278
Highly active compounds against COVID-19
granted -
US 11738038
Highly active compounds against COVID-19
granted -
US 11707480
Highly active compounds against COVID-19
granted -
US 11690860
Treatment of HCV infected patients with cirrhosis
granted -
US 11679079
Ophthalmic formulations and related methods
granted -
US 11679078
Ophthalmic formulations and related methods
granted -
US 11278493
Ophthalmic formulations providing durable ocular lubrication
granted -
US 10946033
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 10906928
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
granted -
US 10894804
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
granted -
US 10888529
Vehicles for the transfection of miRNAs
granted -
US 10874687
Highly active compounds against COVID-19
granted -
US 10875885
β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment
granted -
US 10870673
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 10870672
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 10815266
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 10711029
Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
granted -
US 10610597
Polycarbonates bearing aromatic N-heterocycles for drug delivery
granted -
US 10519186
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
granted -
US 10239911
Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 10202412
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
granted -
US 10005811
β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 10000523
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 9919027
Lipid nanoparticle of polymyxin
granted -
US 9828410
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 9717797
Polycarbonates bearing aromatic N-heterocycles for drug delivery
granted -
US 9267151
STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
granted -
US 7638550
Pyrrolic derivatives with histone deacetylase inhibitory activity
granted
Frequently asked questions
How many patents does Atea Pharmaceuticals have?
35 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Atea Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.